<DOC>
	<DOC>NCT01718639</DOC>
	<brief_summary>This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in postprandial heartburn. The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in terms of efficacy for postprandial heartburn treatment.</brief_summary>
	<brief_title>Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<criteria>Postprandial heartburn (e.g. after a highfat meal) in at least 2 months prior to the study (at least 2 times a week) Not receiving prescribed treatment for heartburn, reflux or upper gastrointestinal disorders Written informed consent is a prerequisite for subject enrollment. Gastrointestinal bleeding within 12 months prior to the study Difficulty swallowing (dysphagia) History of or symptoms suggestive of ZollingerEllison syndrome, oesophageal or gastric malignancy, gastric or duodenal ulcer, pernicious anaemia, Barrett's oesophagus or systemic sclerosis Participation in other studies within the last 30 days prior to entry or during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>